Thus, it is important to elucidate the question whether patients with initially diagnosed RAS-mutated tumors retain this status during the complete disease course or whether RAS-mutated tumor cells are negative selected following chemotherapy and the tumor subsequently turns into a wild-type status, which could be potentially treated with anti-EGFR agents. This evidence concerns the gene EGFR and neoplasm.